ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,127.79
1.26%
US Tech 100
17,448.80
0.17%
다우존스 지수
38,675.68
1.18%
Bitcoin
65,206.08
1.89%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Pharvaris NV (PHVS)

  7. Pharvaris NV (PHVS) 뉴스

PHVS Pharvaris NV

22.60
0.00 (0.00%)
시간외 단일가
최종 업데이트: 17:09:39
15분 지연
기업명 주식 심볼 시장 주식 타입
Pharvaris NV PHVS 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
0.00 0.00% 22.60 17:09:39
개장가 저가 고가 종가 전일 종가
22.60
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
11/04/202405:10GLOBEPharvaris Reports Fourth Quarter and Full Year 2023..
11/04/202405:08GLOBEPharvaris Appoints David Nassif, J.D., as Chief Financial..
04/04/202419:50GLOBEPharvaris to Present Deucrictibant Clinical Data at the CIIC..
18/03/202419:50GLOBEPharvaris Announces Phase 3 Clinical Study Design for..
12/03/202402:51EDGAR2Form 144 - Report of proposed sale of securities
07/03/202406:40EDGAR2Form F-3ASR - Automatic shelf registration statement of..
07/03/202406:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/03/202420:50GLOBEPharvaris to Present Deucrictibant Clinical Data at Upcoming..
05/03/202420:50GLOBEPharvaris to Participate in the Leerink Global Biopharma..
22/02/202420:50GLOBEPositive Results from CHAPTER-1 Phase 2 Study of..
16/02/202420:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/02/202420:50GLOBEPharvaris Announces Extraordinary Meeting of Shareholders
08/02/202406:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/02/202406:46EDGAR2Form 144 - Report of proposed sale of securities
26/01/202420:50GLOBEPharvaris to Present at the WSAAI Annual Meeting 2024
22/01/202421:35DJNPharvaris Says FDA Lifted Clinical Hold on Application for..
22/01/202420:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/01/202420:50GLOBEPharvaris Announces FDA Lifting of the Clinical Hold of..
08/01/202421:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/01/202420:50GLOBEPharvaris Provides Business Update and Outlines 2024..
03/01/202406:29EDGAR2Form 144 - Report of proposed sale of securities
09/12/202308:00GLOBEPharvaris Presents Deucrictibant Clinical Data and Analysis..
09/12/202306:50EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/12/202306:17EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07/12/202306:36EDGAR2Form 144 - Report of proposed sale of securities
06/12/202321:08EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
06/12/202321:02GLOBEPharvaris Announces Pricing of $300 Million Underwritten..
06/12/202320:52EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/12/202320:50GLOBEPharvaris Announces Positive Top-line Phase 2 Data from the..
30/11/202320:50GLOBEPharvaris to Present at the GA²LEN UCARE Conference 2023
15/11/202320:50GLOBEPharvaris Appoints Stefan Abele, Ph.D., as Chief Technical..
10/11/202301:00GLOBEPharvaris Presents Deucrictibant Clinical Data and..
02/11/202319:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/11/202319:50GLOBEPharvaris Reports Third Quarter 2023 Financial Results and..
30/10/202319:50GLOBEPharvaris To Present at the ACAAI 2023 Annual Scientific..
13/10/202319:50GLOBEPharvaris To Present at the APAAACI 2023 International..
04/10/202320:34GLOBEPharvaris To Present at the CIIC Fall 2023 Conference
20/09/202305:23EDGAR2Form 144 - Report of proposed sale of securities
19/09/202319:50GLOBEPharvaris To Participate in the 2023 Cantor Global..
06/09/202319:51GLOBEPharvaris To Present at the 18th German Allergy Congress
06/09/202319:50GLOBEPharvaris To Participate in the Morgan Stanley 21st Annual..
02/09/202307:02EDGAR2Form 144 - Report of proposed sale of securities
25/08/202305:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
23/08/202319:50GLOBEPharvaris To Present at the 2023 HAEi Regional Conference..
17/08/202313:15EDGAR2Form EFFECT - Notice of Effectiveness
10/08/202308:00EDGAR2Form 144 - Report of proposed sale of securities
10/08/202307:38EDGAR2Form 144 - Report of proposed sale of securities
07/08/202323:16EDGAR2Form F-3 - Registration statement by foreign private issuers
07/08/202319:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/08/202319:50GLOBEPharvaris Reports Second Quarter 2023 Financial Results and..

최근 히스토리

NASDAQ
PHVS
Pharvaris NV
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유